Summary.-Thymidine incorporation in vitro by remission lymphocytes from a total of 6 patients with acute myeloid leukaemia (AML) was measured following stimulation by autochthonous and allogeneic AML blasts and cell lines. The early peak response to autochthonous blasts in 2 of these patients 
THE SEARCH for antigens characteristic of neoplastic cells which may have diagnostic or therapeutic significance has been one of the primary aims of tumour immunology. The evidence of such antigens specific to human leukaemic cells is based largely on observations that DNA synthesis by lymphocytes from patients in remission is stimulated by autochthonous acute-phase leukaemic blasts (Fridman and Kourilsky, 1969; Viza et al., 1969; Powles et al., 1971) though the existence of such antigens on lymphoblastic leukaemic cells using this test has been disputed (Schweitzer, Melief and Eijsvoogel, 1973) .
The clinical value of this test appears to be as an indicator of prognosis and minimal residual disease. Thus patients whose lymphocytes are strongly stimulated by autochthonous blasts are more likely to enter and remain in remission for more than one year, than those whose lymphocytes are weakly stimulated .
In view of the potential clinical importance of the lymphocyte stimulation test in predicting remission length and residual disease, its possible use in monitoring the effects of immunotherapy (Powles et al., 1971; Gutterman et al., 1973a) and the induction of cell-mediated cytotoxicity (Taylor, Harris and Freeman, 1976) , further clarification of its nature is long overdue. This study investigates variables determining the response to autochthonous AML blasts by lymphocytes from AML patients in remission who are receiving allogeneic AML blasts as part of their immunotherapy.
MATERIALS AND METHODS
Patients: remission induction.-The 6 patients (JC, MI, AH, HH, SW and BH) whose responses to autochthonous leukaemic blasts and allogeneic cells were measured were all treated with induction chemotherapy consisting of cytosine arabinoside (Ara-C, 2-0 mg/kg body wt) administered i.v. in 5-day courses with gaps of 5 days, and daunorubicin (1.5 mg/kg body wt) in 6 courses coinciding with the first day of Ara-C. When the patients were in full remission (<50 blasts in the bone marrow) they received a single course of Ara-C/daunorubicin as above, and commenced immunotherapy one week later.
Maintenance treatment.-The patients were then randomized to receive weekly immunotherapy according to one . In addition, one of the groups of patients received monthly maintenance chemotherapy consisting of 5-day courses of Ara-C (2-0 mg/kg orally) and daunorubicin (I-5 mg/kg), the latter at 2-monthly intervals.
Leukae mic blasts. 107/ml into sterile 5 ml glass ampoules, which were then sealed and cooled to 4°C. The ampoules were frozen at a rate of -1°C/min to -150°C in a programmed freezer (R201, G. V. Planer Ltd) and then stored at -120°C in the vapour phase of a liquid N2 refrigerator (LR-320, Union Carbide, Darlington).
Preparation of responding lymphocytes.-Venous blood obtained from remission AML patients was anticoagulated with heparin (10 iu/ml) or by defibrination with sterile glass beads. A lymphocyte-enriched leucocyte population was obtained by layering the whole blood-in some cases diluted 1: 1 with sterile Ringer solution (Baxter Laboratories, Thetford, Norfolk)-over 5 ml (whole blood) or 3 ml (diluted blood) of a mixture of 9% Ficoll (Pharmacia, Uppsala, Sweden) and 33% Triosil (Nyegaard, Oslo, Norway) (24 parts: 10 parts) in straight-sided flat-bottomed glass tubes (100 x 14 mm) followed by centrifugation at 4°C for 40 min at 400 g (B6yum, 1968) . The interface of the plasma and Ficoll/Triosil-containing lymphocyte-enriched leucocytes was gently removed with glass pipettes, placed in glass centrifuge tubes and washed twice by centrifugation in TC199/HEPES containing 10% foetal calf serum (FCS) (Welleome Laboratories, Kent). The cells were adjusted to 1-5 x 106/ml by counting in trypan blue.
Preparation of stimulating cells.-The autochthonous and allogeneic cells used as stimulating cells were obtained from storage in liquid N2, and were thawed rapidly by agitation of the ampoules in a water bath at 37°C, after which the cells were washed once in cold TC199/HEPES containing 10% FCS.
Allogeneic cell lines used as stimulating cells in some of the experiments were derived originally from Burkitt's lymphomata and designated Raji or Jijoye (see Klein, 1973 In 2 of the 3 patients (AH and JC) significant lymphocyte stimulation was elicited by autochthonous blasts (Fig. la,  b) , whilst no stimulation occurred in the third patient (MI, Fig. lc) , whose lymphocytes in the mixed culture incorporated significantly less 3H-TdR than in the control.
Two of the patients (AH and MI) were receiving monthly maintenance chemotherapy in addition to weekly immunotherapy (I + C), though this probably does not account for the lack of response by MI to autochthonous blasts, since
(1) the patient tested subsequently (unpublished) failed to respond to her autochthonous blasts, and (2) the patient responded to allogeneic imimunotherapy blasts (Fig. lc) . The peak response to the autochthonous blasts in patients JC and AH occurred 2 to 3 days after the initiation of the culture (48 72 h). By the seventh day of culture, autochthonous blast-stimulated lymphocytes from AH ( Fig. la) incorporated significantly less 3H-TdR than in the control cultures, and there was a steady decline in 3H-TdR incorporation by the autochthonous blaststimulated lymphocytes from patient JC (Fig. lb) , a patient receiving immunotherapy only as maintenance treatment.
All patients had a positive response to allogeneic cells. In the case of patient AH (Fig. la) the autochthonous response was compared with the response to allogeneic Raji cells, the latter having a much greater stimulatory effect on remission lymphocytes than autochthonous blasts. The control Raji cultures incorporated significant amounts of 3H-TdR, Fig. 2a ) increased as the number of stimulating blasts increased, whilst the response of the other patient (MI (I + C), Fig. 2b ) was unaffected by an increase in the number of stimulating blasts, and was in fact significantly inhibited by autochthonous blasts. In the test on lymphocytes from patient JC (Fig. 2a) we observed that an S : R ratio of 0-6: 1 was non-stimulatory, though at a ratio of 2-6: 1 autochthonous blasts induced significant stimulation. However, in view of the fact that other tests using the S: R ratio 0-6: 1 (or 1: 1.5 as described in the Methods) were found to give stimulation, though possibly of a lower magnitude, we used this ratio routinely to preserve our store of leukaemic blasts.
Effect of preparation on the stimulatory capacity of AML blasts For routine tests, lymphocytes were stimulated with mitomycin C-treated autochthonous blasts. This method of cell preparation was more specifically examined in comparison with other methods in further tests at a later stage of remission in patient JC, and in 2 other patients (HH and BH). Autochthonous blasts were treated with mitomycin C, x-irradiated at 2 x 103 rad, heated to 56°C for 10min, or were left untreated. All cell preparations were washed once following treatment, and adjusted to the Table I show that 2 of the 3 patients tested (HH (I) and JC (I)) responded positively to one or more of the cell preparations, whilst the third patient (BH (I)) failed to respond to any of his autochthonous blasts, irrespective of treatment. The two positive responders (HH and JC) responded to mitomycin C-treated autochthonous blasts and, whereas the responses of patient JC to cells prepared by the other 3 methods, including heat killing, were positive, the response in patient HH to untreated cells was not significantly positive and was in fact significantly inhibited by heated and x-irradiated cells.
Effect of blast-cell-conditioned medium
One possible explanation for the stimdlatory effect of autochthonous AML blasts on remission lymphocytes could be that the blasts release soluble mitogenic factors which lack antigenic specificity. Such factors would not be detected in the control cultures used here since lymphocytes were cultured separately from blasts. The possibility that non-specific blast cell mitogenic factors are able to stimulate remission lymphocytes was tested in the following experiments. Autochthonous AML blasts were pre-incubated in culture medium for 3-5 days at concentrations of 0-5-1-0 x 106 cells/ml. The cells were then centrifuged and the supernatant medium passed through 0.22 ,um Millipore filters to produce blast-cellconditioned medium. Mixed and control cultures were set up as previously described, in both media. The results of experiments with remission lymphocytes from 3 patients (HH, JC and SW, all receiving I) obtained at further stages of treatment than in the previous experiments are shown in Table II Table I test cells in control culture (Fridman and Kourilsky, 1969; Viza et al., 1969; Powles et al., 1971) . Although similar lymphocyte responses have been observed to cells from solid tumours (Ambus et al., 1974; Vanky et al., 1973) they are not restricted to neoplastic cells. Thus, autochthonous PHA-transformed lymphoblasts (Weksler, 1973) and lymphoid cell lines (Han, Moore and Sokal, 1971; Flier et al., 1970) (Bach, Solliday and Stambuck, 1970; Thorsby, 1974) but a shift in the peak MLC response to an earlier day is known to result when the donor of the responding lymphocytes had been pre-immunized in vivo with allogeneic lymphocytes (Bondevik and Thorsby, 1974a) . The implication of the early MLC response is that the responding cells are a pre-immune clone recognizing B:LA serologically defined antigens (Bondevik and Thorsby, 1974b) .
A possible explanation of the early autochthonous response observed in the present study is that a similar pre-immune lymphocyte clone reacts in vitro to leukaemia-associated antigens. Further evidence in favour of this explanation is provided by Gutterman et al. (1972) , who observed that patients were able to respond to autochthonous solubilized leukaemia blasts, though these extracts failed to stimulate allogeneic normal lymphocytes. Moreover, Char et al. (1973) showed that autochthonous blast cell membrane extracts induced skin reactivity in AML patients more frequently than allogeneic extracts. Lymphocyte responses to acute-phase AML blasts do not, in our opinion, represent nonspecific thymidine incorporation as suggested by Schweitzer et al. (1973) The antigens of autochthonous leukaemic blasts causing lymphocyte stimulation have never been identified, the reason undoubtedly being the difficulty in identifying the specificity of the clone of responding lymphocytes. Although an intact and viable cell may be necessary to induce a lymphocyte response, there are difficulties in using untreated stimulating blasts, firstly because spontaneous DNA synthesis in the control cultures may mask specific stimulation, and secondly because any allogeneic leucocytes in the stimulating cell preparation may induce a two-way MLC reaction, though careful checking of the treatment of patients before obtaining the autochthonous blasts can often exclude this difficulty. Nevertheless, x-irradiation or, better still, mitomycin C treatment of the blasts is the method of choice, though in one case (JC) in this study, even heattreated blasts caused stimulation.
Although stimulation of lymphocytes by autochthonous lymphoid cell lines was thought to have been caused by blastogenic (or mitogenic) factors (Flier et al., 1970) others have failed to find evidence of such factors (Han et al., 1971; Birnbaum, Siskind and Weksler, 1972) . No evidence could be found in the present study that mitogenic factors were released by acute-phase blasts when tested on control cultures or mixed cultures of blasts and lymphocytes. In-deed the response both to autochthonous and allogeneic cells was in somie cases suppressed in the presence of soluble blast-cell-derived factors. The suppressive effect of AML pre-treatment serum on the PHA response of normal lymphocytes (Walker et al., 1973) may be caused by such AML blast-derived suppressive factors. There is no doubt that stimulation of remission lymphocytes by acutephase leukaemic blasts is of a much lower magnitude than that observed by allogeneic cell lines. Interestingly, allogeneic AML blasts appear to have a similar stimulatory capacity to autochthonous blasts. The similarity between the stimulatory capacity of autochthonous and allogeneic transformed cell lines (Birnbaum et al., 1972) and acute-phase mononucleosis cells (Junge, Hoekstra and Deinhardt, 1971 .) has led Steel et al. (1973) to speculate that autochthonous stimulation could be caused by virally coded modifications of histocompatibility antigens. Strong evidence that the virus responsible may be Epstein-Barr (EB) virus has been presented by Bausher and Smith (1973) , who suggested that the response to autochthonous cell lines may represent the recognition of EB antigens by a pre-immune lymphocyte clone. The T-cell-derived cell line MOLT-4 is one of the few cell lines lacking EB nuclear antigens (EBNA, Reedman and Klein, 1973; Svedmyr, Deinhardt and Klein, 1974) and is characterized by its lack of stimulatory antigens when tested in mixed culture with allogeneic lymphocytes (Han and Minowada, 1973) . However, the stimulatory capacity of autochthonous AML blasts cannot be ascribed to EB antigens, since AML blasts lack EBNA (Svedmyr et al., 1974; Taylor, G. M., unpublished) , though the possibility that some other antigen is involved is suggested by the finding of leukaemia-associated nuclear antigen in AML blasts (Klein et al., 1 973) .
Elution of AML blasts with glycine-HCI failed to increase their stimulatory capacity, and argues against the participation of facto rs blocking surface antigens, such as have been demonstrated by Vanky et al. (1973) on a minority of solid tumours. Indeed the presence of membrane immunoglobulin on AML blasts, which correlated with their ability to stimulate remission lymphocytes (Gutterman et al., 1973b) could be regarded as playing a crucial part, perhaps complexed with antigen, in initiating the autochthonous response.
